Sponsor or institution

Clinical trials and research at Xiamen Amoytop Biotech Co., Ltd.

• 7Clinical trials
• 1New in 30 days
• 1Country

Newest trials

All recruiting trials (7)

• Long-term Inpegsomatropin Treatment for Idiopathic Short Stature: Extension of Phase III Study

  This extension study tests whether continuing Inpegsomatropin injections helps kids with Idiopathic Short Stature who finished a prior phase 3 trial.

  Recruiting at 27 sites Xiamen Amoytop Biotech Co., Ltd. · Beijing and 26 other locations · NCT07894341

• ACT201 Injection in Healthy People and in Chronic Hepatitis B Patients

  This Phase 1 trial tests ACT201 against a placebo in healthy adults and in people with chronic hepatitis B who are on stable antiviral therapy to see if it is safe and how the body handles it.

  Recruiting Phase 1 Xiamen Amoytop Biotech Co., Ltd. · Shanghai, Shanghai Municipality · NCT07741461

• Inpegsomatropin vs Givopegsomatropin for short stature in girls with Turner syndrome

  A 52-week, multicenter, randomized study tests whether Inpegsomatropin injections help prepubertal girls with Turner syndrome grow taller compared with a known treatment.

  Recruiting at 49 sites Phase 3 Xiamen Amoytop Biotech Co., Ltd. · Anyang and 50 other locations · NCT07614152

• Easy-to-Use Growth Hormone Deficiency Treatment: A New Injectable for Adults

  This phase 2b-like study tests whether a new injectable called Inpegsomatropin can be safely given in multiple escalating doses to adults with growth hormone deficiency, to see if it helps them and how it behaves in the body.

  Recruiting at 6 sites Phase 2 Xiamen Amoytop Biotech Co., Ltd. · Beijing and 5 other locations · NCT07551804

• Once-weekly inpegsomatropin versus daily growth hormone for children born small for gestational age

  This trial will test whether once-weekly inpegsomatropin helps children born small for gestational age grow as well as daily recombinant human growth hormone.

  Recruiting at 49 sites Phase 3 Xiamen Amoytop Biotech Co., Ltd. · Beijing and 48 other locations · NCT07309562

• Once-weekly inpegsomatropin versus daily recombinant growth hormone for children with idiopathic short stature

  This trial will test whether a once-weekly inpegsomatropin injection works as well and is as safe as daily recombinant human growth hormone in prepubertal children with idiopathic short stature.

  Recruiting at 38 sites Phase 3 Xiamen Amoytop Biotech Co., Ltd. · Hefei, Anhui and 37 other locations · NCT06927310

• Peginterferon α-2b for patients with resistant or intolerant Essential Thrombocythemia

  This study is testing if a new medication called Peginterferon α-2b can help people with essential thrombocythemia who haven't had success with or can't tolerate their current treatment.

  Recruiting at 8 sites Phase 2 Xiamen Amoytop Biotech Co., Ltd. · Beijing and 7 other locations · NCT06552429

Quick answers

How many clinical trials run by Xiamen Amoytop Biotech Co., Ltd. are recruiting right now?

7, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 3, Phase 2: 2, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →